Lecap Asset Management Ltd. Acquires Shares of 7,544 Shockwave Medical, Inc. (NASDAQ:SWAV)

Lecap Asset Management Ltd. purchased a new stake in Shockwave Medical, Inc. (NASDAQ:SWAV - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 7,544 shares of the company's stock, valued at approximately $1,438,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Harbour Investments Inc. raised its stake in shares of Shockwave Medical by 3.3% during the first quarter. Harbour Investments Inc. now owns 1,300 shares of the company's stock valued at $282,000 after acquiring an additional 41 shares during the last quarter. Snowden Capital Advisors LLC increased its stake in shares of Shockwave Medical by 1.4% in the first quarter. Snowden Capital Advisors LLC now owns 3,035 shares of the company's stock valued at $658,000 after buying an additional 43 shares during the period. Exchange Traded Concepts LLC raised its position in shares of Shockwave Medical by 11.5% during the third quarter. Exchange Traded Concepts LLC now owns 483 shares of the company's stock worth $96,000 after acquiring an additional 50 shares during the last quarter. Lindbrook Capital LLC raised its holdings in Shockwave Medical by 64.8% during the 3rd quarter. Lindbrook Capital LLC now owns 150 shares of the company's stock worth $30,000 after purchasing an additional 59 shares during the last quarter. Finally, Treasurer of the State of North Carolina lifted its position in shares of Shockwave Medical by 0.4% in the 3rd quarter. Treasurer of the State of North Carolina now owns 16,390 shares of the company's stock worth $3,263,000 after purchasing an additional 60 shares during the period. 95.35% of the stock is owned by institutional investors.

Insider Activity

In other Shockwave Medical news, CEO Douglas Evan Godshall sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $217.59, for a total transaction of $2,175,900.00. Following the completion of the transaction, the chief executive officer now owns 141,057 shares in the company, valued at approximately $30,692,592.63. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Frederic H. Moll sold 60,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $257.39, for a total value of $15,443,400.00. Following the completion of the sale, the director now directly owns 287,521 shares of the company's stock, valued at approximately $74,005,030.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Douglas Evan Godshall sold 10,000 shares of the stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $217.59, for a total value of $2,175,900.00. Following the sale, the chief executive officer now owns 141,057 shares in the company, valued at approximately $30,692,592.63. The disclosure for this sale can be found here. Insiders sold a total of 103,813 shares of company stock worth $25,938,579 over the last 90 days. Corporate insiders own 3.40% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on SWAV. SVB Leerink reissued a "market perform" rating and set a $335.00 target price (down previously from $361.00) on shares of Shockwave Medical in a research note on Monday, April 8th. Wells Fargo & Company boosted their price objective on Shockwave Medical from $200.00 to $210.00 and gave the company an "equal weight" rating in a research note on Friday, February 16th. Wolfe Research reiterated a "peer perform" rating on shares of Shockwave Medical in a report on Friday, April 5th. Leerink Partnrs cut Shockwave Medical from an "outperform" rating to a "market perform" rating in a report on Friday, April 5th. Finally, CL King reaffirmed a "neutral" rating on shares of Shockwave Medical in a research report on Monday, April 8th. Ten equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $309.11.

Shockwave Medical Stock Performance

Shares of SWAV stock traded down $0.49 during trading hours on Friday, reaching $327.70. The company had a trading volume of 2,078,088 shares, compared to its average volume of 1,943,426. The firm has a market cap of $12.26 billion, a PE ratio of 84.68, a price-to-earnings-growth ratio of 2.46 and a beta of 0.92. The company has a debt-to-equity ratio of 1.09, a quick ratio of 10.73 and a current ratio of 11.76. The business has a fifty day moving average price of $276.65 and a 200-day moving average price of $224.43. Shockwave Medical, Inc. has a one year low of $157.00 and a one year high of $331.58.

Shockwave Medical (NASDAQ:SWAV - Get Free Report) last released its earnings results on Thursday, February 15th. The company reported $1.16 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.24. Shockwave Medical had a return on equity of 23.97% and a net margin of 20.17%. The company had revenue of $202.98 million for the quarter, compared to the consensus estimate of $199.43 million. During the same period in the previous year, the business earned $3.71 earnings per share. Shockwave Medical's quarterly revenue was up 41.0% compared to the same quarter last year. Sell-side analysts predict that Shockwave Medical, Inc. will post 4.9 earnings per share for the current fiscal year.

About Shockwave Medical

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.